Squarepoint’s Matinas BioPharma MTNB Stock Holding History

Squarepoint’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-20,601	Closed	-$72.9K	–	5344
2024 Q3	$72.9K	Buy	+20,601	New	+$131K	﹤0.01%	3936
2023 Q4	–	Sell	-2,961	Closed	-$19.2K	–	4314
2023 Q3	$19.2K	Buy	+2,961	New	+$36.4K	﹤0.01%	3700
2021 Q3	–	Sell	-322	Closed	-$12K	–	3239
2021 Q2	$12K	Sell	322 -7,435	-96%	-$320K	﹤0.01%	3153
2021 Q1	$407K	Buy	7,757 +4,500	+138%	+$302K	﹤0.01%	2177
2020 Q4	$221K	Buy	+3,257	New	+$151K	﹤0.01%	2444
2019 Q1	–	Sell	-710	Closed	-$21K	–	2334
2018 Q4	$21K	Buy	+710	New	+$27.9K	﹤0.01%	1868

Other funds holding MTNB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HIW

Holos Integrated Wealth Kennett Square, Pennsylvania $214M AUM 14.99% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Squarepoint's MTNB Position: Q4 2024 in Review

Squarepoint sold out of Matinas BioPharma (MTNB) in Q4 2024, closing a stake of 20,601 shares — an estimated $72.9K sold.

Squarepoint first reported a position in MTNB in Q4 2018 and held it in 6 quarters. The position peaked at $407K in Q1 2021. 22 funds tracked by Wall St. Rank hold MTNB as of Q4 2024.

Squarepoint reported no remaining Matinas BioPharma position as of Q4 2024 after selling out during the quarter.
Squarepoint sold 20,601 Matinas BioPharma shares in Q4 2024, an estimated $72.9K.
Squarepoint first reported a position in Matinas BioPharma in Q4 2018 and held it in 6 quarters.
Squarepoint's Matinas BioPharma position peaked at $407K in Q1 2021.
22 funds tracked by Wall St. Rank held Matinas BioPharma as of Q4 2024.

Based on Squarepoint's 13F filing for Q4 2024, filed 14 Feb 2025.